Search Results
Your search for ,foR matches 33018 pages
Showing 22101 - 22150Study Examines Global Trends in Ovarian Cancer Mortality Rates
Deaths from ovarian cancer fell worldwide between 2002 and 2012, and are predicted to continue to decline in the United States, European Union (EU) and Japan by 2020, according to new research published by Malvezzi et al in Annals of Oncology. The main reason is the use of oral contraceptives and...
FDA Grants Priority Review to Pembrolizumab for First-Line Treatment of Advanced NSCLC
The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for pembrolizumab (Keytruda), an anti–PD-1 (programmed cell death protein 1) therapy, for the first-line treatment of patients with advanced non–small...
Is Extramedullary Disease at Diagnosis Prognostic in Adult Acute Myeloid Leukemia?
The presence of extramedullary disease at acute myeloid leukemia (AML) diagnosis was not an independent prognostic factor for worse survival, based on an analysis of data from the Eastern Cooperative Oncology Group–American College of Radiology Imaging Network (ECOG-ACRIN) reported by Ganzel...
DNA Methylation Assay May Improve Diagnosis of Cancer of an Unknown Primary
As reported in The Lancet Oncology, Moran et al developed a classifier of cancer type based on microarray DNA methylation signatures (EPICUP assay), which has showed promise in diagnosing cancers of an unknown primary. Study Details The tumor type classifier was developed in a training set of...
Nivolumab in Recurrent Classical Hodgkin Lymphoma: Refreshingly Supportive Data
It is commonly said that if something is too good to be true, it usually is. It is therefore quite refreshing when really good results are replicated in a subsequent study. As reported in The Lancet Oncology by Younes et al1 and reviewed in this issue of The ASCO Post, a phase II trial of...
ASCO Applauds Bold Recommendations From Cancer Moonshot Blue Ribbon Panel
ASCO commended the Cancer Moonshot Initiative Blue Ribbon Panel for its ambitious recommendations to accelerate progress against cancer. “We applaud the Blue Ribbon Panel for its work and the National Cancer Institute's (NCI's) National Cancer Advisory Board for convening the panel,”...
Nivolumab Achieves Response in Most Patients With Classical Hodgkin Lymphoma After ASCT and Brentuximab Vedotin
In a phase II trial reported in The Lancet Oncology by Anas Younes, MD, of Memorial Sloan Kettering Cancer Center, and colleagues, treatment with the anti–PD-1 (programmed cell death protein 1) immune checkpoint inhibitor nivolumab (Opdivo) produced response in two-thirds of patients with...
Weight Watchers and the American Cancer Society Launch Initiative to Support Holistic Health for Breast Cancer Survivors
Weight Watchers International, Inc, has launched Project LIFT—Live Inspired, Fight Together—a new movement, in collaboration with the American Cancer Society, to inspire and guide breast cancer survivors with free resources focused on tackling the unexpected weight gain that can follow breast...
Multitude of Mentors Help Shape an Illustrious Career in Oncology
Sumanta K. Pal, MD, has had a longer career in oncology than many other colleagues his age. Perhaps the reason for that may center on his starting college at the age 13 and medical school at the age of 17. Today this internationally recognized leader in genitourinary cancers is Assistant Professor ...
Clinical Trials Actively Recruiting Patients With Basal Cell Carcinoma
Study Title: Long-Pulsed 1064 nm Nd:YAG Laser Treatment of Basal Cell Carcinoma (BCC) Study Type: Interventional/single-group assignment Study Sponsor and Collaborators: University of California, San Diego; Massachusetts General Hospital Purpose: To evaluate the safety and efficacy of laser...
Management of Merkel Cell Carcinoma
A recent report regarding pembrolizumab (Keytruda) for advanced Merkel cell carcinoma ushered in a more optimistic era in the treatment of this rare but often lethal skin cancer.1 The ASCO Post spoke with one of the field’s leaders, Paul Nghiem, MD, PhD—the first author of the study—about the...
Use of Pembrolizumab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma After Platinum-Containing Therapy
On August 5, 2016, pembrolizumab (Keytruda) was granted accelerated approval for treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma and disease progression on or after platinum-containing chemotherapy.1,2 As a condition of the accelerated approval, Merck is...
Appointments and Awards at the 2016 MASCC/ISOO Annual Meeting
At the 2016 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) International Symposium on Supportive Care in Cancer in Adelaide, Australia, a new President of the organization was announced, and numerous awards were given to outstanding...
Effect of Radiosurgery Alone vs With Whole-Brain Radiotherapy on Cognitive Function in Patients With Brain Metastases
Physicians from Carolinas HealthCare System’s Neurosciences Institute and Levine Cancer Institute are among the authors of a recent study published by Brown et al in JAMA.1 The study showed how among patients with one to three brain metastases, the use of stereotactic radiosurgery alone, compared...
Global Curriculum in Surgical Oncology Outlined by Society of Surgical Oncology and European Society of Surgical Oncology
As reported by Chandrakanth Are, MBBS, MBA, FRCS, FACS, of the University of Nebraska Medical Center, Omaha, and colleagues at the Society of Surgical Oncology (SSO) and European Society of Surgical Oncology (ESSO), the rising global burden of cancer and inequalities in surgical oncology education ...
President Obama Names Margaret Spitz, MPH, to National Cancer Advisory Board
Margaret Spitz, MPH, Professor in the National Cancer Institute (NCI)-designated Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine, has been appointed by President Barack Obama as a member of the National Cancer Advisory Board (NCAB). A renowned expert in molecular...
Matti Aapro, MD, Awarded MASCC’s Distinguished Service Award
Matti Aapro, MD, has been selected as the recipient of the Multinational Association of Supportive Care in Cancer’s (MASCC) 2016 Distinguished Service Award. The Award recognizes meritorious achievement and outstanding contributions to the Society and its mission. Candidates are nominated by their ...
ASCO 2016: Geriatric Oncology Highlights
Clinical trials focused on older adults with cancer were featured prominently at the 2016 ASCO Annual Meeting. There was a plenary session in glioblastoma, a clinical symposium on immunotherapy, and multiple educational lectures highlighting the growing literature and unique challenges in the...
AACI Names Three New Members to Board of Directors
The Association of American Cancer Institutes (AACI) has announced the election of Karen E. Knudsen, PhD; Norman Sharpless, MD; and Eduardo Sotomayor, MD, to the AACI Board of Directors. The new Directors’ 3-year terms will start on October 23, 2016, during the AACI/ Cancer Center Administrators...
FDA Grants Orphan Drug Designation to CD4CAR for the Treatment of Peripheral T-Cell Lymphoma
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for chimeric antigen receptor–engineered T cells directed against the target protein CD4 (CD4CAR) for the treatment of peripheral T-cell lymphoma. William Tse, MD, Chief of the Blood and Marrow Transplantation Division ...
Interim PET-Adapted Treatment in Advanced Hodgkin Lymphoma
The ability to cure a majority of patients with advanced Hodgkin lymphoma is one of the major milestones of success in the combination chemotherapy era. It has been over 40 years since Bonadonna and colleagues in Milan developed the ABVD regimen (doxorubicin, bleomycin, vinblastine, and...
Continued ABVD vs Omission of Bleomycin (AVD) After Negative Imaging Findings in Advanced Hodgkin Lymphoma
In a phase III trial reported in The New England Journal of Medicine, Peter Johnson, MD, of the Cancer Research UK Centre, University of Southampton, and colleagues found similar efficacy with continued ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) vs omission of bleomycin (AVD) after...
Immune Analysis of On-Treatment Longitudinal Biopsies Predicts Response to Melanoma Immunotherapy
Immune response measured in tumor biopsies during the course of early treatment predicts which melanoma patients will benefit from specific immune checkpoint blockade drugs, researchers at The University of Texas MD Anderson Cancer Center found in a report published by Chen et al in Cancer...
FDA Approves Blinatumomab for Use in Pediatric Patients With Ph-Negative Relapsed or Refractory B-Cell Precursor ALL
The U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for blinatumomab (Blincyto) to include new data supporting the treatment of pediatric patients with Philadelphia chromosome (Ph)-negative relapsed or refractory B-cell precursor acute...
Posttreatment Problems Surveyed in African American Breast Cancer Survivors
Although there is some overlap, past research has shown that the challenges faced by African American breast cancer survivors differ somewhat from Caucasian women. But the studies that demonstrated difference were not designed to explore those challenges in depth. Now new research from Thomas...
Study Finds Minimal Residual Disease Assessment Improves Prediction of Outcome in CLL Responders
Assessment of minimal residual disease was associated with improved prediction of outcome in responders, as well as complete responders, in patients with chronic lymphocytic leukemia (CLL) who respond to treatment. Kovacs et al reported these findings, which are based on an analysis of two phase...
Does Intensified Postoperative Chemotherapy for High-Grade Osteosarcoma Benefit Poor Responders to Preoperative Therapy?
In a phase III trial (EURAMOS-1) reported in The Lancet Oncology, Marina et al found no improvement in event-free survival by adding postoperative ifosfamide/etoposide to cisplatin, doxorubicin, and methotrexate in patients with newly diagnosed high-grade osteosarcoma who responded poorly to...
Continuation of Docetaxel May Improve Survival in Metastatic Castration-Resistant Prostate Cancer
The number of docetaxel cycles completed was associated with improved overall survival among men with metastatic castration-resistant prostate cancer receiving docetaxel, prednisone, and lenalidomide (Revlimid; DPL) or docetaxel/prednisone (DP), in the phase III Mainsail trial. de Morrée et...
Hypofractionated Radiotherapy for Localized Prostate Cancer: A New Standard of Care?
For at least the past quarter of a century, radiobiologists and radiation oncologists have debated the role of hypofractionation (fewer total fractions with a higher dose per fraction) for prostate cancer. The debate stems from the unique radiobiology of prostate cancer and the best means to...
James Morgan, PhD, Named Scientific Director at St. Jude
St. Jude Children’s Research Hospital has named James Morgan, PhD, Scientific Director and Executive Vice President. Dr. Morgan held the Interim Scientific Director post since 2015 and was formerly Chair of the Department of Developmental Neurobiology. As Scientific Director, Dr. Morgan will...
Roundup of Selected Abstracts in Multiple Myeloma, Acute and Chronic Leukemia, and Advanced Lymphoma
In June 2016, the European Hematology Association Congress convened in Copenhagen, Denmark. The educational and scientific program highlighted state-of-the-art clinical practice and the latest findings in hematology research. The ASCO Post brings its readers brief summaries of some of the important ...
Learn How to Implement the Psychosocial Distress Screening Quality Care Standard at the 2017 APOS Annual Conference
The National Cancer Institute (NCI)-funded Psychosocial Distress Program is an educational program desgined to train cancer care clinicians over 2 years to develop, implement, and maintain comprehensive psychosocial distress screening programs. The 1st year of the Screening for Psychosocial...
For High-Grade and Aggressive Non-Hodgkin Lymphomas, Treat Adults Like Children
Outcomes for adults with high-grade and aggressive non-Hodgkin lymphomas (NHLs) appear to be better when these patients are treated with pediatric-inspired protocols, according to Mitchell S. Cairo, MD, Chief of the Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Maria...
Phase III Study Launches in Patients With Small Cell Lung Cancer
On August 2, 2016, PharmaMar announced the start of a pivotal phase III ATLANTIS study evaluating the efficacy and safety of lurbinectedin (PM1183), a novel synthetic tetrahydroisoquinoline that targets active transcription. The study is evaluating lurbinectedin combined with doxorubicin vs...
Expert Point of View: Brian Burkey, MD, MEd
“This study pointed out what most head and neck/reconstructive surgeons know: Complex free flap reconstructions are associated with a relatively high readmission rate,” commented session co-moderator Brian Burkey, MD, MEd, Vice Chairman and Section Head of Head & Neck Surgery and Oncology, Head ...
Predictors of Readmission in Patients Requiring Free Tissue Reconstruction for Head and Neck Cancer
Certain factors increase the risk of unplanned readmission in the month after head and neck cancer resection requiring free tissue reconstruction, finds an analysis of data from the National Surgical Quality Improvement Program (NSQIP) of the American College of Surgeons.1 Nearly 1 in 10 patients...
Expert Point of View: M. Boyd Gillespie, MD, MSCR
“This study is actually surprising to me, because earlier studies of that particular antibody as a single therapy for this disease, salivary duct carcinoma, showed it was not very effective, with only 10% to 15% response rates,” session co-moderator, M. Boyd Gillespie, MD, MSCR, Professor and Vice ...
Good Showing for Trastuzumab/Docetaxel Combination Against Salivary Gland Carcinoma
The combination of trastuzumab (Herceptin) and docetaxel seems to be highly active in patients with unresectable advanced HER2-positive salivary gland carcinoma of the ductal subtype, according to interim data from an open-label, single-arm phase II trial.1 More than two-thirds of patients had a...
Expert Point of View: Michael L. Hinni, MD
“Endoscopic transoral surgeons have used corticosteroids for years before, during, and after transoral operations to prevent presumptive airway edema and to reduce the risks of tracheostomy,” commented one of the session co-moderators, Michael L. Hinni, MD, Chair of the Department of...
Benefits Seen From Extending Steroids After Transoral Robotic Surgery for Head and Neck Cancer
Patients undergoing transoral robotic surgery for head and neck cancer may experience improvements in some outcomes when given an extended course of corticosteroids, finds a randomized controlled trial reported at the 9th International Conference on Head and Neck Cancer.1 Relative to peers given...
Expert Point of View: William B. Armstrong, MD
“This work is intriguing and may have clinical potential,” commented session co-moderator William B. Armstrong, MD, Professor of Clinical Otolaryngology–Head and Neck Surgery and Chair, Department of Otolaryngology–Head and Neck Surgery, at the University of California, Irvine, Orange, ...
Nerve Stimulation During Oncologic Neck Dissection May Help to Preserve Shoulder Function
Electrical stimulation of the spinal accessory nerve during neck dissection for head and neck cancer may reduce the development of shoulder dysfunction, according to a double-blind randomized controlled trial.1 A year after surgery, patients given intraoperative electrical stimulation had...
Discrepancies Between Current ASCO-CAP Guidelines on HER2 Amplification Testing and Designations in BCIRG Trials
In an analysis reported in the Journal of Clinical Oncology, Press et al found notable discrepancies between recent ASCO–College of American Pathologists (ASCO-CAP) changes in the recommendations for evaluation of HER2 amplification by fluorescent in situ hybridization (FISH) and FISH scores...
Early-Stage Prostate Cancer Incidence Rates Decline, Distant-Stage Disease Rates Unchanged in 2013
Jemal et al described findings indicating a continued decline in the incidence of localized/regional-stage prostate cancer at 2 years after the U.S. Preventive Services Task Force recommendation against routine prostate-specific antigen (PSA) screening in men aged ≥ 50 years in 2011, in a letter ...
Use of Lugol’s Iodine Stain May Reduce the Need for Repeat Resection of Oral and Oropharyngeal Cancers
By identifying residual dysplasia in the tumor bed, Lugol’s iodine staining may improve pathologic outcomes with resection of oral and oropharyngeal cancers, according to interim findings of a UK randomized controlled trial reported at the 9th International Conference on Head and Neck Cancer.1...
Is Obesity a Prognostic Factor for Improved Survival in Metastatic Renal Cell Carcinoma?
In a study investigating the clinical and biologic effects of body mass index on treatment outcomes in patients with metastatic renal cell carcinoma, Albiges et al found that obese patients treated with targeted therapy had improved survival and progression-free survival compared with patients with ...
Study Finds Gemcitabine/Cisplatin Improved Outcome vs Fluorouracil/Cisplatin in Recurrent or Metastatic Nasopharyngeal Carcinoma
In a Chinese phase III trial reported in The Lancet, Zhang et al found that gemcitabine/cisplatin improved progression-free survival vs fluorouracil/cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. Study Details In the open-label trial, 362 patients from 22 sites in...
Palliative Care 2016: 'Mystery Shopper' Study Finds Barriers to Accessing Palliative Care Services at Major Cancer Centers
A team of researchers, using a novel approach, found that while many cancer centers offer palliative and supportive care services, patients may face challenges when trying to access them. The study showed that expanding awareness and education to patient-facing cancer center employees about such...
Palliative Care 2016: Family Caregivers for Patients With Advanced Cancer Often Experience High Levels of Anxiety, Depression
A new multistate survey showed that nearly one-quarter to one-third of family caregivers of patients with high-mortality cancers experience high levels of depression and anxiety symptoms. The study also found that family caregivers can spend over 8 hours per day providing care and that as this time ...
Palliative Care 2016: Early Palliative Care Improves Coping, Quality of Life for Patients With Incurable Cancers
A randomized clinical trial found that introducing palliative care shortly after a diagnosis of certain metastatic cancers greatly increases a patient’s coping abilities, as well as overall quality of life. Researchers also found that early integration of palliative care results in an...
